Department of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, 95817, USA.
Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544.
Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6-minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, approximately 1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean +/- SD [range] 6-minute walk distance (6MWD) was lower in boys with DMD than in controls (366 +/- 83 [125-481] m vs. 621 +/- 68 [479-754] m; P < 0.0001; unpaired t-test). Test-retest correlation for boys with DMD was high (r = 0.91). Stride length (R(2) = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease-related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials.
行走异常是杜氏肌营养不良症(DMD)的突出表现。我们修改了 6 分钟步行测试(6MWT),将其作为 DMD 患者的疗效评估指标,并在 21 名能行走的 DMD 男孩和 34 名健康男孩(年龄 4 至 12 岁)中对其进行了评估。DMD 男孩测试了两次,两次测试时间间隔约为 1 周;对照组只测试了一次。两组的年龄、身高和体重相似。所有测试均完成。DMD 男孩跌倒后迅速从跌倒中恢复,无受伤。DMD 男孩的平均 6 分钟步行距离(6MWD)低于对照组(366 +/- 83 [125-481] m vs. 621 +/- 68 [479-754] m;P < 0.0001;非配对 t 检验)。DMD 男孩的测试-重测相关性很高(r = 0.91)。对于 DMD 男孩和对照组来说,步幅长度(R² = 0.89;P < 0.0001)是 6MWD 的主要决定因素。改良的 6MWT 是可行和安全的,记录了与疾病相关的行走受限,具有可重复性,并为 DMD 自然史和治疗试验提供了新的疗效评估指标。